Harvard Apparatus Regenerative Technology, Inc. CEO He Junli reported purchasing 361,905 common shares in the September 11, 2026 private placement for $380,000, or $1.05 per share, and converting bridge notes into 683,725 shares at $1.05 per share. The notes represented $717,911 of outstanding principal and accrued interest and were canceled in full. He also purchased 6,725 shares in multiple transactions from September 15 to September 23, 2026, at a weighted average price of $2.15 per share. No Rule 10b5-1 plan is reported.
Harvard Apparatus Regenerative Technology, Inc. (HRGN) entered into Securities Purchase Agreements with certain investors for a private placement of 2,703,727 shares of common stock at $1.05 per share, for an aggregate purchase price of $2,838,911. The private placement closed on September 11, 2026.
As part of the transaction, Chief Executive Officer Jerry (Junli) He acquired 683,725 shares through the conversion and cancellation of $717,911 of principal and accrued interest under bridge promissory notes previously issued to him, which were cancelled in full at closing. The shares were issued in reliance on Section 4(a)(2) and Rule 506 under the Securities Act as sales to accredited investors.
Harvard Apparatus Regenerative Technology, Inc. (HRGN), a Delaware biotechnology company, filed a Form D for a new exempt private offering of equity securities under Regulation D Rule 506(b). The notice reports $2,838,911 of securities sold and a further $161,089 remaining to be sold. The first sale in this offering occurred on September 11, 2026, and no finders' fees are reported, with $0 shown for such expenses. The company indicates that some proceeds may be used for working capital and other general corporate purposes, which may include payment of salaries and other fees to the executive officers and directors listed, including the chief financial officer who signed the notice.
Harvard Apparatus Regenerative Technology, Inc. reported second-quarter 2026 product revenue of $414,000, all from consumer health products in Asia, up from $317,000 a year earlier. For the first six months of 2026, product revenue was $640,000, a 77% increase over 2025.
The company remains deeply loss-making, with a Q2 net loss of $1.7 million and a six‑month net loss of $3.3 million, only slightly better than 2025. At June 30, 2026, cash and cash equivalents were just $351,000, total assets $1.7 million, liabilities $3.1 million, and stockholders’ deficit $1.4 million, reflecting an accumulated deficit of about $109.9 million.
Management states that existing cash, a related‑party bridge loan of $500,000, and about $0.4 million in investor advances in escrow are expected to fund operations only into the fourth quarter of 2026, and explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
Harvard Apparatus Regenerative Technology, Inc. granted CEO and director Junli He a nonqualified stock option covering 1,200,000 shares of common stock at an exercise price of $1.09 per share, expiring on July 21, 2036. The award consists of a 600,000-share time-based tranche and a 600,000-share performance-based tranche with distinct vesting conditions.
The time-based portion includes 100,000 shares vesting upon signing of the award agreement, then 16,667 shares vesting monthly from September 1, 2026 until a total of 600,000 shares vest, all subject to continued employment. The performance-based portion vests in four milestone tranches tied to a controlling-stake sale or national exchange listing, share-price performance, additional capital raising of at least $10,000,000, and other conditions, and becomes fully vested upon a Sale Event or Change of Control under the company’s equity plan.
Harvard Apparatus Regenerative Technology, Inc. entered into two short-term bridge loan arrangements with its Chairman and Chief Executive Officer, Junli He, providing a total of $400,000 in funding. A $200,000 Bridge Note dated May 8, 2026 and a second $200,000 Bridge Note dated July 16, 2026 each bear a fixed annual interest rate of 8%, calculated on a 360-day year.
For each note, all principal and accrued interest are due on the earlier of the company's next capital raise with at least $5,000,000 in gross proceeds or the one-year anniversary of the note's date. If the company completes an equity financing of at least $200,000 before maturity, the lender may elect to convert the outstanding balance into the new securities at the financing price. The notes are prepayable at any time without penalty, include customary covenants and events of default, and were approved as related party transactions by the disinterested directors. Aggregate principal outstanding under the Bridge Notes is $400,000.
Harvard Apparatus Regenerative Technology, Inc. entered into a loan arrangement on April 13, 2026, under which Chairman and Chief Executive Officer Junli He agreed to provide the company with a $300,000 Bridge Note. The note carries a fixed annual interest rate of 8% and includes covenants and customary events of default.
The principal and accrued interest become due on the earlier of the company’s next capital raise with at least $5,000,000 in gross proceeds or April 13, 2027. The Bridge Note allows optional conversion at the lender’s discretion. This report also corrects a prior classification error, re-reporting the loan as an Item 1.01 entry into a material definitive agreement rather than a termination under Item 1.02.
Harvard Apparatus Regenerative Technology, Inc. held its Annual Meeting of Stockholders on June 18, 2026. Stockholders elected three Class I Directors — Junli (Jerry) He, James Shmerling, and Mao Zhang — each for a one-year term ending at the 2027 annual meeting.
Shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 14,077,329 votes for. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 12,467,264 votes for.
Harvard Apparatus Regenerative Technology, Inc. reported a Q1 2026 net loss of $1.6 million, slightly better than the $1.7 million loss a year earlier. Product revenue rose to $226,000 from $45,000, driven by expanded Consumer Health products in Asia. Operating expenses were $1.8 million, with research and development at $0.56 million and general and administrative at $1.05 million. Cash and cash equivalents fell to $419,000 from $1.35 million at year-end, while accumulated deficit reached about $108.2 million, leaving total assets of $1.8 million and equity of $92,000. Management discloses substantial doubt about the company’s ability to continue as a going concern and expects existing cash plus a subsequent $0.5 million bridge loan to fund operations only into the second quarter of 2026, requiring additional financing to sustain activities.
Harvard Apparatus Regenerative Technology, Inc. filed an 8-K to share that the first patient has been treated with its Cellspan™ Esophageal Implant (CEI) in a Phase 1 feasibility and safety clinical trial at the Mayo Clinic in Rochester, Minnesota.
The CEI is a combination product using a modified polyurethane CellFrame™ mesh scaffold seeded with a patient’s own adipose-derived Mesenchymal Stromal Cells, temporarily supporting tissue growth before scaffold removal 21–42 days after implantation. The company highlights this as a key milestone in its effort to offer a regenerative option for life‑threatening esophageal disease, which currently relies on highly invasive procedures.